Table 1 Patient demographics and comorbidities

Age, median (IQR)

56(48–63)

57(49–63)

56(46–62)

0.093

Male gender (%)

92(42.4%)

62(52.5%)

30(30.3%)

0.001

BMI, median (IQR)

23.0(21.0–26.4)

23.1(21.6–26.1)

22.9(20.5–27.4)

0.376

With other site VTE

Pulmonary thromboembolism

8(3.7%)

4(3.4%)

4(4.0%)

1.000

Lower extremity Deep vein thrombosis

17(7.8%)

9(7.6%)

8(8.1%)

1.000

VTE history

13(6.0%)

8(6.8%)

5(5.1%)

0.776

Bleeding history

11(5.1%)

4(3.4%)

7(7.1%)

0.234

Primary cancer

 < 0.001

 Breast

59(27.2%)

25(21.2%)

34(34.3%)

 Lymphoma

40(18.4%)

33(28.0%)

7(7.1%)

 Gastrointestinal

61(28.1%)

42(35.6%)

19(19.2%)

 Gynecology

25(11.5%)

10(8.5%)

15(15.2%)

 Lung

32(14.7%)

8(6.8%)

24(24.2%)

With metastasis (%)

90(41.5%)

45(38.1%)

45(45.5%)

0.276

ECOG performance status

0.002

  0

60(27.6%)

28(23.7%)

32(32.3%)

  1

92(42.4%)

43(36.4%)

49(49.5%)

  2

65(30.0%)

47(39.8%)

18(18.2%)

Antiangiogenic

therapy used

53(24.4%)

37(31.4%)

16(16.2%)

0.009

Underlying diseases/conditions

 Cardiovascular disease

41(18.9%)

20(16.9%)

21(21.2%)

0.424

 Diabetes

22(10.1%)

18(15.3%)

4(4.0%)

0.007

 Abnormal renal function (30 ml/min ≤ CrCl < 60 ml/min)

12(5.5%)

5(4.2%)

7(7.1%)

0.363

 Reduced platelet (Platelet count < 100 × 10^9/L)

13(6.0%)

8(6.8%)

5(5.1%)

0.593

 Anemia(Hemoglobin < 130 g/L for man, < 120 g/L for woman)

35(16.1%)

17(14.4%)

18(18.2%)

0.451

Non-single lumen PICC

8(3.7%)

6(5.1%)

2(2.0%)

0.295

Left arm insertion

34(15.7%)

26(22.0%)

8(8.1%)

0.005

Suspect exit site infection

9(4.1%)

3(2.5%)

6(6.1%)

0.306

Treatment duration (days, IQR)

180(125, 180)

180(120, 180)

180(126, 181)

0.229

Outcome

Recurrent VTE

4(1.8%)

2(1.7%)

2(2.0%)

1.000

Major bleeding

0

0

0

NA

Clinical related nonmajor bleeding

19(8.8%)

6(5.1%)

13(13.1%)

0.037

Death from any cause

3(1.4%)

2(1.7%)

1(1.0%)

1.000